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Abstract
Introduction: Many published accounts have shown that quality improvement (QI) initiatives within medical practice settings can
increase vaccination rates. Project ECHO is a telementoring platform that uses video conferencing technology to educate and
support healthcare professionals through case-based learning and brief lectures. This manuscript explores the results of a learning
collaborative focused on combining QI and Project ECHO to increase human papillomavirus (HPV) vaccination rates within pediatric
practices. Methods: The American Academy of Pediatrics (AAP) recruited 3 AAP chapters that then recruited individual pediatricians
and their practices for participation. Participants responded to surveys regarding chapter and pediatrician experience and satisfaction. Impact on HPV immunization rates (HPV initiation, series completion, and missed opportunities to vaccinate during visits) was
measured using practice reports of chart reviews to AAP’s data aggregator, which produced run charts. Results: Thirty-four pediatricians within 8 practices completed the project; 1 practice withdrew. Physicians self-reported increased confidence in communicating
with vaccine-hesitant families and implementing QI activities. We analyzed practice run charts utilizing QI run chart rules and found
nonrandom change towards improvement for aggregate missed opportunities to vaccinate but not for HPV vaccine initiation or series
completion. Conclusions: An HPV QI learning collaborative improved participant confidence in HPV vaccine communication and
QI skills and decreased missed opportunities to vaccinate. Future projects should consider a more extended project period or more
frequent data collection to reduce data variability to make it easier to spot nonrandom changes. (Pediatr Qual Saf 2021;6:e377; doi:
10.1097/pq9.0000000000000377; Published online December 28, 2020.)

INTRODUCTION

these cancers, the Advisory Committee on
Immunization Practices recommends HPV
vaccination for all adolescents at age 11
or 12 years.2 While rates for HPV vaccination have continued to rise since
2008, national rates remain well below
the Healthy People 2020 goal of 80% for
completion of the HPV vaccine series.3 As
of 2019, 71% of adolescents ages 13–17
years had started the series, and 54.2% were
up-to-date.4 There are significant geographic disparities in HPV vaccination rates. The HPV vaccination
rate of adolescents living in non-metropolitan statistical
areas was almost ten percentage points lower than that
of peers living in metropolitan statistical areas principal
cities.4
Quality improvement (QI) initiatives can increase HPV
vaccination rates.5,6 From 2014 to 2019, the American
Academy of Pediatrics (AAP) implemented HPV vaccination QI projects across the United States through its network of chapters. In 2018, the Extension for Community
Healthcare Outcomes (ECHO) model was integrated
into existing QI projects, which aimed to teach pediatric
providers QI methodology to improve HPV vaccination
rates.
ECHO is a telementoring platform that uses video
conferencing technology to educate and support healthcare professionals through case-based learning and brief

Human papillomavirus (HPV) infection is
associated with more than 43,000 new cancers in the United States annually, including cervical, vaginal, vulvar, penile, anal,
and oropharyngeal cancers.1 To prevent
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to offset their costs for a 9-month project. Participating
pediatricians were eligible to receive 25 American Board
of Pediatrics Maintenance of Certification (MOC) Part 4
credits at no cost. The project received an exemption from
the AAP Institutional Review Board.

lectures on various health conditions. Unlike telemedicine, this model does not establish a provider-patient relationship but builds primary care providers’ capacity to
manage health conditions encountered within their scope
of practice. The model started as a way to treat Hepatitis
C in New Mexico and has expanded to address more
than 100 diseases and conditions across 37 countries.7,8
In their 2018 report, the National Vaccine Advisory
Committee recommended using telementoring platforms
to improve HPV vaccine provider education in rural and
underserved communities.9 This manuscript is the first
description of the ECHO model’s adaptation to assess HPV
vaccination rates utilizing QI methodology in primary care.
This description of the ECHO QI learning collaborative on
HPV vaccination (1) examines the feasibility, acceptability,
and sustainability of Project ECHO for immunization QI
work within a multi-state learning collaborative; (2) analyzes the impact of participation on HPV vaccination outcomes; (3) identifies lessons learned that could be applied
to future projects using ECHO for QI.

Project Design and Curriculum

Multidisciplinary faculty, including pediatricians, immunization education experts, an obstetrician/gynecologist
with HPV vaccination expertise, and a QI coach served
as hub faculty. Hub faculty developed a 9-session curriculum (Table 1) to teach QI processes and evidence-based
guidelines around HPV vaccination, including a strong
provider recommendation, reminder/recall messaging,
and provider prompts.11,12
Practices chose which vaccination strategies to implement and test in plan-do-study-act (PDSA) cycles
(described below). Each month for 9 months, program
participants convened for 1 hour via video conferencing.
The authors taught the curriculum twice each month to
facilitate participation across multiple time zones and fit
busy providers’ needs. If a provider missed the monthly
live sessions, the opportunity to view an archived recording was available. Each session included a 15–20-minute
educational lesson covering critical topics in HPV vaccination and QI, followed by a practice-led de-identified
case presentation and group discussion. In the first few
months, the cases focused on individual patient encounters (eg, how to engage with parents with specific questions). As the QI work advanced, practices presented cases
on specific change ideas (eg, vaccinating patients starting
at age 9 years versus age 11 or 12 years) that providers
had tested within their clinic settings. Run charts showing
both aggregate and practice level data also were discussed
during the video conferences.

METHODS
Learning Collaborative Structure

The AAP is a membership organization of 67,000 pediatricians focused on improving all children’s health. The
national AAP works closely with 59 United States and 7
Canadian independent AAP chapters. AAP chapters are
individually incorporated organizations, usually defined
by state boundaries, and tasked with furthering the AAP
mission and addressing state-specific child health challenges. From 2014 to 2019, the AAP Hub and Spoke
Initiative focused on Improving HPV Vaccination Rates
has been supported by a Centers for Disease Control and
Prevention cooperative agreement to focus on increasing
HPV vaccination rates across the country.10 As part of the
HPV QI Initiative, the national AAP served as the “hub”
to support QI projects while AAP chapters served as
“spokes,” implementing the QI projects in their respective
states. A critical goal was to provide training and experience in QI to chapters for HPV vaccination, leading to
sustainability beyond the funding period.

QI Methodology

The improvement science model used and taught to participants for this work was the Model for Improvement.
Langley13 developed this model, described in the
Improvement Guide: A Practical Approach to Enhancing
Organizational Performance. The model emphasizes
3 questions: What are we trying to accomplish? How
will we know that a change is an improvement? What
changes can we make that will result in improvement?
The aim statement for this project was: to improve practice’s HPV vaccination initiation, completion, and missed
opportunity rates with patients aged 11–14 by 20% by
the end of the 9-month project. We taught practices to
use “change ideas”—evidence-based strategies, preferably
shown to work elsewhere, to test in their current setting.
Participants used rapid PDSA cycles to test change ideas.
As the office-based teams gained confidence that their
change ideas were feasible and would lead to improvement, they implemented the changes, that is, made them
standard practice.13,14 Practices chose which strategies
to test in rapid PDSA cycles, how many strategies to try,

Chapter and Practice Recruitment, Ethics

Recruitment took place in 2 phases. First, the national
AAP recruited AAP chapters through a competitive application process. Selected AAP chapters then recruited pediatric practices from their respective states or jurisdictions,
utilizing their contacts with local practices from previous AAP projects, and list-serves to recruit participants.
Practices had to agree to identify a practice leader for the
project, complete monthly data collection and case forms,
attend 9 virtual meetings, and hold 8 team meetings to
discuss project outcomes and goal progress. Recruited
practices that met program requirements completed a
memorandum of understanding to enroll in the project.
Chapters offered participating practices $1,000–$2,000
2
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Table 1. The Quality Improvement Learning Collaborative Curriculum Topics, By Session
Session 1
Session 2
Session 3
Session 4
Session 5
Session 6
Session 7
Session 8

Overview of HPV and the ECHO model
Quality improvement basics: PDSA cycles, aim statements, change concepts
Understanding your data: annotated run charts, baseline data, measure sets (outcome, process, balancing), data collection tools
HPV vaccine communication
Office logistics for improving vaccination rates
Centers for Disease Control and Prevention update: HPV vaccine
HPV vaccine: effectiveness and safety
Maintaining momentum: sustaining your quality improvement project

Session 9

Applying spread principles

and which to implement. They could adjust strategies
throughout the project in response to improvements seen.
Thus, for each data cycle (1 month of data collection),
many PDSA cycles were performed.

collected data from charts of a minimum of 15 eligible
patients age 11–14 seen consecutively within that data
cycle (30 days). For each visit, practice personnel recorded
the visit type and the patient’s age, sex, if they were due
for the HPV vaccine, if they received the HPV vaccine at
that visit (if applicable), and the reason for not getting vaccinated (if applicable). If a practice did not see at least 15
age-eligible patients during the month, practice personnel
entered the data on all eligible patients seen that month.
Using the QIDA system, practices could produce run
charts on their monthly rates of HPV vaccination initiation, completion, and missed opportunities to vaccinate.
For this project, we defined outcomes as follows. HPV
vaccination initiation was the number of patients who
received their first dose at the time of the visit, divided by
the number of patients who were due for the first dose.
HPV vaccination completion was the number of patients
who received dose 2 or 3 (depending on schedule) at the
time of the visit, divided by the number of patients who
were due for their last dose at the visit. Missed opportunities to vaccinate was the number of patients who did
not receive the HPV vaccine during their visit, divided by
the number of patients due for an HPV vaccine dose. For
this analysis, the authors applied run chart rules to identify trends in HPV vaccination rates at the aggregate and
practice level. Some run chart rules require a median for
interpretation, and experts recommend having at least 10
data points. However, Provost and Murray14 note that it is
acceptable to plot medians with fewer data points. Data
will cross the median frequently as part of normal random
variation, without having any QI-driven changes introduced to the process. A reduction in median crossings is,
therefore, likely related to the team’s tests of change. We
interpreted fewer than 3 crossings of the median for our 8
data points to indicate a meaningful change for this project.

Outcome: Program Participation and Experience

AAP staff tracked fulfillment of project requirements,
including monthly teleconference attendance, submission
of cases, and submission of chart review data to AAP’s
data aggregator. Participating AAP chapters reported on
their project experience twice (mid-way and post-completion), and answered 12 questions to identify project
updates, feedback, challenges, successes, current reach,
and project partnerships.
Practice participants reported on their project experience each month throughout the project utilizing a postvideo conference survey on the session’s speakers, pace,
and desired future topics. Each month practices also submitted information on the change ideas that they were
testing that month using rapid PDSA cycles. For the first
half of the project, each month, practices submitted a
case presentation form that described a specific case of an
11–14-year-old patient and whether or not they received
the HPV vaccine at that visit. Upon completing the project, practice participants answered a 27-item survey that
included questions on their overall project experience,
HPV vaccination and QI practices, and the demographic
data for themselves and their practices. We assessed participant confidence in their QI skills by asking them to
rate their ability to serve as a consultant on HPV vaccination QI efforts within (1) their clinic, and (2) their
community. For each of the 2 questions, they could rate
themselves as novice, competent, or expert. Questions
focused on vaccination practices and confidence change
were analyzed in SPSS statistical analysis software (IBM
Corp. Released 2017. IBM SPSS Statistics for Windows,
Version 25.0, Armonk, N.Y.) using the McNemar-Bowker
test for statistical significance.

RESULTS
Feasibility, Participation, and Satisfaction

Outcome: HPV Vaccination

Chapter Participation and Sustainability
Four AAP chapters applied, and 3 were selected: Arizona,
New Jersey, and Oregon. Each chapter recruited between
2 and 4 practices to participate. Video conference sessions
were held monthly from January to September 2018. To
build capacity and enhance sustainability among the 3
AAP chapters, each chapter’s staff received training in

For 8 of the 9 project months, practices uploaded chart
review data on HPV vaccination outcomes into AAP’s
Quality Improvement Data Aggregator (QIDA). QIDA is
an AAP developed and owned web-based data aggregation system that allows individual providers to securely
enter practice-level data and view real-time data reports.
Practices conducted retrospective chart reviews and
3

Pediatric Quality and Safety

QI Learning Collaborative for HPV Vaccination

the ECHO model, participated in all ECHO sessions, and
organized and managed 1 of the 9 sessions.
On a 5-point Likert scale (very successful, somewhat
successful, neutral, somewhat unsuccessful, and not successful), all 3 chapters rated the project very or somewhat
successful. Chapters mentioned several aspects that made
this learning collaborative successful, including gaining
QI methodology skills, strengthening relationships with
the participating pediatric practices and providers, and
creating and disseminating HPV vaccination resources
among the learning collaborative. All 3 chapters strongly
agreed that this project increased their capacity to implement QI activities. Chapters shared that the advanced QI
tools and methodology gained in this learning collaborative transferred over to their other QI projects and, in
1 case, precipitated the establishment of a QI committee
within their state. In November 2018, after completing
this learning collaborative, all 3 participating chapters
launched an HPV immunization learning collaborative
as ECHO hubs, recruiting between 5 and 10 additional
practices each for participation.

identify patients due for HPV vaccine before the physician
encounter (75%). Four practices (50%) began offering the
HPV vaccine at younger ages (9 or 10 years) than before
the project. Two practices implemented a reminder/recall
system, and 1 practice developed standing orders for HPV
vaccination. Practices reported testing between 4 and 7
different change ideas over the 9-month project period.

HPV Vaccination Outcomes

Throughout the 8-month data collection period, aggregate rates of missed opportunities to vaccinate at all visit
types fell by 13 percentage points (38%–25%). Aggregate
HPV vaccine initiation rates for patients ages 11–14 years
increased by 15 percentage points (54%–69%), and HPV
vaccination completion rates decreased by 2 percentage
points (88%–86%). Utilizing a QI run chart rule14 that less
than 3 crossings of the median suggest nonrandom change,
the aggregate missed opportunities run chart data crossed
the median once, suggesting a nonrandom change towards
improvement. However, the aggregate HPV vaccination
initiation data crossed the median line 3 times, and aggregate HPV vaccination completion data crossed the median
4 times, indicating no change during the project (Fig. 2).
Three practices used run chart rules to achieve improvement in 1 or more project measures at the practice level.
One practice met the rule for series initiation, series completion and missed opportunities, 1 for initiation and
completion, and 1 for completion alone. One practice had
nearly a steady worsening across all 3 measurements. The
remaining 6 practices had fluctuations in their data.

Practice/Provider Participation and Experience
Chapters recruited 9 practices, among which 8 (5 suburban, 2 urban, and 1 a combination of suburban and
urban) completed the project. One practice withdrew in
the first few months, due to a staff emergency. Two to
8 individuals per practice participated, including pediatricians, nurse practitioners, and office staff (total = 42,
pediatricians = 34). Pediatrician participation varied by
practice, with a range of 50%–100% of a practice’s providers participating (Fig. 1). The average attendance at
each video conference session was 34. After 1 practice
withdrew from the project, the remaining 34 pediatricians completed the project.
In the post-project survey, providers (physicians and
nurse practitioners) reported increased knowledge and confidence (along a continuum from novice to competent to
expert) on HPV vaccine communication with hesitant families. Similarly, participants were more likely to report they
were “competent” or “expert” to serve as a consultant for
HPV vaccination QI efforts in their clinic and community
(Table 2). Providers also shared that they enjoyed learning
from others in the collaborative, the interactive design, the
curriculum, and the presenters of the educational material.
Some providers reported a preference for a shorter project
period and shorter conference sessions (Table 3).

DISCUSSION AND LESSONS LEARNED
Volunteer practices showed the feasibility of this 9-month
AAP-organized ECHO QI learning collaborative focused
on HPV vaccination using video-conferencing during
monthly, live, interactive sessions. Aggregate data on
missed opportunities showed an improvement. Three of
the final 8 practices showed improvement in at least 1
of 3 key measures (series initiation, series completion,
missed opportunities).

Feasibility, Acceptability, and Sustainability

This project demonstrates that the Project ECHO model
can be used for a multi-state QI learning collaborative.
Utilizing a hub and spoke model, the AAP was able to
recruit chapters from diverse states. One of the benefits
of this model is that it enhanced the likelihood of sustainability of ongoing learning collaboratives. All participating chapters mastered the integrated Project ECHO/
QI process through their participation, including their
required facilitation of a live session; all rated the project as successful. Having AAP chapters act as a “spoke”
(participant) before serving as a “hub” (leader) was novel
to the AAP ECHO program structure. All 3 chapters have
since gone on to lead their own HPV vaccination QI
learning collaboratives.

Implementation Strategies

Practices chose various evidence-based change ideas to
increase HPV vaccination rates and then tested those
ideas using PDSA cycles (Table 4). Most practices chose
to offer HPV vaccine at both sick (88%) and follow-up
visits (75%), conducted all-staff training sessions (75%),
implemented a provider communication strategy focused
on the bundled recommendation and cancer prevention
(75%), and developed processes to review charts and
4
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Fig. 1. The learning collaborative structure. The American Academy of Pediatrics (AAP) provided training, tools, technical assistance,
and project oversight. Three AAP chapters recruited practice sites and verified that practices within their state met requirements for
data collection and attendance. Nine sites participated, and their characteristics are listed.

for participation in pediatric QI programs, probably
played a role in project completion among pediatricians
and should continue to be used in future projects.5,6,16 We
did not offer any tangible incentive to the nurses and staff
in these pediatricians’ offices, and they were less likely
than pediatricians to attend the calls, attending only 1 or
2 meetings. Offering a greater diversity of credits could
incentivize various medical professionals to achieve multidisciplinary teams in future projects.
The use of video conference technology in learning settings, which has become extremely popular because of the
COVID-19 pandemic, can allow for fuller engagement and
enhanced communication and satisfaction among participants.17,18 In this project, some participants either did not
have video capability or chose to participate via audio
rather than video, which may have negatively affected
engagement. Faculty leading the monthly learning sessions
felt that future ECHO projects should ensure broad video
participation. Allowing more time for familiarization with
the technology, in the first session or during onboarding,
may increase the use of the video component.

One limitation of the project identified by chapters was
the challenge with practice recruitment. This difficulty
occurred despite the incentive of MOC Part 4 credit for
physicians and funding for practices to offset participation costs, including data reporting. The limited timeframe for recruitment (6 weeks) may have been a factor.
Future ECHO QI iterations should allow more time for
practice recruitment. One of the ECHO model’s strengths
is the ability, through video conferencing, to reach rural
practices that may not otherwise have access to subject
matter experts. The impact of the ECHO model in rural
locations has been previously demonstrated in the areas
of hepatitis C treatment, and behavioral health.7,15 While
rural areas were not a specific focus of this project (and
no rural practices enrolled) and given lower rates of HPV
vaccination in rural areas, this could be a focus for future
recruitment. Of note, chapters mentioned above that went
on to lead their own collaboratives were able to recruit
3 rural practices to participate. We suspect having more
time for recruitment facilitated this success.

Provider and Staff Level

Impact on HPV Immunization

Despite challenges with recruitment, pediatricians had
high retention, with more than 88% completing the project. MOC Part 4 credit, frequently used as an incentive

While only offering 8 monthly data points, the project did
allow for examining the impact on HPV immunization
5
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Table 2. Post-project Clinical Staff Self-assessment of HPV Vaccination Learning Collaborative Competencies (Survey
results from September 2018) (n = 31)

Educate my staff about the importance of the HPV vaccine
Novice
Competent
Expert
Introduce HPV vaccine in a way that optimizes parents’ vaccine confidence
Novice
Competent
Expert
Communicate with families and caregivers who are hesitant about HPV vaccination
Novice
Competent
Expert
Communicate with families and caregivers who decline/delay HPV vaccination
Novice
Competent
Expert
Serve as a consultant within my clinic for HPV vaccination quality improvement
efforts
Novice
Competent
Expert
Serve as a consultant within my community for HPV vaccination quality
improvement efforts
Novice
Competent
Expert
Implement methods to increase HPV vaccination rates by increasing visit
attendance (ie, reminders, recall)
Novice
Competent
Expert
Implement methods to increase HPV vaccination rates by increasing captured
opportunities (ie, standing orders, practitioner prompts)
Novice
Competent
Expert

Before Project

After Project

Frequency, n (%)

Frequency, n (%)

10 (32.2)
19 (61.3)
2 (6.5)

0 (0.0)
14 (45.2)
17 (54.8)

0.000*

17 (54.8)
11 (35.5)
3 (9.7)

0 (0.0)
15 (48.4)
16 (51.6)

0.000*

20 (64.5)
6 (19.4)
5 (16.1)

0 (0.0)
18 (58.1)
13 (41.9)

0.000*

23 (74.2)
7 (22.6)
1 (3.2)

1 (3.2)
22 (71)
8 (25.8)

0.000*

17 (54.8)
13 (41.9)
1 (3.2)

1 (3.2)
19 (61.3)
11 (35.5)

0.000*

20 (64.5)
11 (35.5)
0 (0.0)

2 (6.5)
24 (77.4)
5 (16.1)

0.000*

14 (45.2)
16 (51.6)
1 (3.2)

3 (9.7)
18 (58.1)
10 (32.2)

0.001*

17 (54.8)
13 (41.9)
1 (3.2)

1 (3.2)
21 (67.7)
9 (29)

0.000*

McNemar
Bowker Test

Table 3. Qualitative Comments Participants Shared About the Learning Collaborative, From Retrospective Survey
What providers enjoyed about the learning collaborative
Increase in confidence
   “I felt much more confident speaking with parents about the HPV vaccine because of this program.”
   “Our HPV vaccination rates have increased, and our staff is more game to answer parents’ questions and concerns about the HPV vaccine.”
   “This project changed my confidence and approach. I used to recommend the vaccine but now I offer it as a lifesaving cancer eliminating vaccine.”
   “This project has reshaped the way we offer HPV vaccine in our office for the better. We have better ways to introduce the vaccine and
  educate families.”
The collaborative learning network
   “The interaction with other practices to hear what they are doing for their PDSA cycles was the best part.”
   “I liked sharing ideas with other practices.”
   “I learned from the many offices participating across the United States.”
   “Interaction with other practices was invaluable.”
The interactive design
   “Everyone could ask questions.”
   “The discussions were great.”
The curriculum and speakers
   “Learning about the quality improvement method was helpful.”
   “The more we understand the diseases the better we can educate families on the importance of vaccinating.”
   “The clear presentations and guest speakers were the best part of this project.”
   “My favorite aspect was learning how to understand our data better.”
What participants would improve about the learning collaborative
The length of the project or monthly session
   It could be fewer weeks.”
   “Shorter time period.”
   “There were too many sessions and cycles.”
   “Shorter sessions like 30 minutes rather than an hour.”
Too much time spent on introductions each session
   “Avoid prolonged introductions which allows for more discussion time.”
   “I recommend not having everyone introduce themselves in the beginning. That took a very long time.”
Repetition of project curriculum
   “The quality improvement education seemed redundant.”
   “Some of the material was repetitive.”

6
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Table 4. Number of Practices that Tested Specific Change
Ideas, as Described in Monthly Practice Reports (Number
of Practices = 8)
Change Idea
Offer HPV vaccine at follow-up visits
Offer HPV vaccine at sick visits
All staff training session
Communication strategy: bundle recommendation,
cancer prevention message
Checking charts pre-visit to identify patients due for
HPV
Handout patient education materials
Offer the vaccine at age 9 or 10 (instead of 11 or 12)
Reminder/recall
Offer vaccine at age 11 (instead of 12)
Standing orders for HPV vaccine
Scheduling next HPV vaccine dose

and completion would follow, given this decrease in
missed opportunities. Future projects should consider
a more extended project period or more frequent data
collection to reduce data variability to make it easier to
spot nonrandom changes. Given that some participants
reported they felt the project duration was too long, more
frequent data collection might be the most acceptable
solution.
In the pre/post-analysis, improvements were seen in
aggregate missed opportunities and initiation rates,
but not series completion, which remained stable at
around 80%. This result is likely due to a combination of improvement being more difficult when rates
are already high and the project’s short duration.
Other HPV vaccination QI projects have demonstrated
improvements across all 3 measures, including series
completion, but their initial completion rates were
lower.5,6,16 Additionally, several participating practices tested the recommendation to offer the HPV vaccine starting at 9–10 years of age. As a result of this
change, improved immunization rates would not have

Number of
Practices, N (%)
6 (75)
7 (86)
6 (75)
6 (75)
6 (75)
5 (63)
4 (50)
2 (25)
1 (13)
1 (13)
1 (13)

rates. In the run chart analysis, extrapolating on the fewer
than 3 crossings of the median rule for our 8 data points,
the only aggregate missed opportunities improved over
this project period. If this project continued for more than
8 months, we would expect improvements in initiation

Fig. 2. The learning collaborative aggregate level run chart data of HPV vaccination initiation, completion, and missed opportunities
during the 8 monthly project data collection.
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been captured in the data, as we included only charts of
patients age 11–14 years of age. Future projects should
consider collecting data starting at age 9 years as pediatricians move towards earlier HPV vaccination in alignment with AAP recommendations.19,20
Only 3 out of the 8 practices demonstrated positive
HPV immunization results throughout the collaborative.
These practices did not differ in the type or number of
evidence-based changes implemented compared to other
practices. They may have differed in the degree to which
they fully implemented changes across the entire practice.
The practice that demonstrated improvement across all 3
measures (initiation, completion, and missed opportunities) was a solo practitioner. Future collaboratives should
identify and address practice barriers to system-level
change.

3.

4.

5.
6.

7.
8.
9.

CONCLUSIONS
This learning collaborative aimed to engage multiple AAP
chapters and pediatric practices to teach QI skills and
improve HPV vaccination rates using the Project ECHO
telementoring platform. At the chapter level, the collaborative demonstrated success in satisfaction and in teaching the necessary skills to allow all participating chapters
to go on to lead HPV QI learning collaboratives of their
own. At the practice level, participants gained confidence
in HPV vaccine communication and QI skills. The collaborative demonstrated early improvements in reducing missed opportunities to vaccinate, while the impact
on HPV vaccination initiation and completion lagged.
Future projects should be extended for more than 8 data
cycles or use more frequent data collection to capture
this change and further identify barriers to system-level
change.
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